Basic, translational, and clinical scientists focusing on multiple myeloma must have access to molecularly characterized cell line model systems, and especially to clinically-annotated fresh and frozen primary tissue samples, to test and validate their hypotheses. The main objective ofthe Myeloma Tissue Core is to work with each SPORE Project, Core, and Program to insure efficient procurement, storage, and distribution of laboratory and clinical tissue samples at the M. D. Anderson Cancer Center. Validated standardized operating procedures have been established for all activities, and continuous communication between the investigators, research nurses, biostatisticians. and hematopathologists will provide for optimal tissue collection, standardized processing, accurate analysis, and safe storage of each sample. These samples will be associated with relevant patient clinical and laboratory data obtained and maintained in accordance with all applicable regulatory guidelines. This Tissue Core will also be used for novel and robust biomarker development and accurate testing of translational hypotheses. There are four specific aims for this Core:
Specific Aim 1. To develop and maintain a repository of intact cells, serum, DNA, RNA, and protein derived from blood, bone marrow, and other tissue specimens obtained from patients with plasma cell dyscrasias at the M. D. Anderson Cancer Center. Samples are collected and processed at the time of diagnosis, during therapy, in remission, or at relapse. This Core will distribute tissue specimens to SPORE investigators for analysis, while providing comprehensive hematopathologic characterization with detailed annotation of parameters of collection and preservation. The Tissue Core also maintains a collection of myeloma cell lines, and will act as a centralized repository for the storage and distribution of newly developed cell lines.
Specific Aim 2. To maintain a comprehensive, prospective, interactive database with detailed clinical and pathologic data for patients with plasma cell dyscrasias.
Specific Aim 3. To facilitate inter- and intra-SPORE collaborations, and collaborations with non-SPORE investigators, through acquisition and distribution of clinical sample resources to and from SPORE investigators and others within the M. D. Anderson Cancer Center, as well as with other national or international sources. This includes developing and sharing the informatics systems with other SPORE sites.
Specific Aim 4. To provide stock and customized reverse phase protein arrays to SPORE investigators.

Public Health Relevance

The Myeloma Tissue Core will provide basic, translational, and clinical scientists focusing on multiple myeloma with access to molecularly characterized cell line model systems, and especially to clinically annotated fresh and frozen primary tissue samples to test and validate their hypotheses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-04
Application #
8543583
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$102,296
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Glitza, Isabella C; Lu, Gary; Shah, Rupin et al. (2015) Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma. Leuk Lymphoma 56:602-7
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Hong, Bangxing; Li, Haiyan; Zhang, Mingjun et al. (2015) p38 MAPK inhibits breast cancer metastasis through regulation of stromal expansion. Int J Cancer 136:34-43
Shi, Qiuling; Wang, Xin Shelley; Li, Guojun et al. (2015) Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer 121:1138-46
Wang, Xin Shelley; Shi, Qiuling; Williams, Loretta A et al. (2015) Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma 56:1335-41
Parmar, S; Kongtim, P; Champlin, R et al. (2014) Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant 49:1036-41
Chen, Zheng; Orlowski, Robert Z; Wang, Michael et al. (2014) Osteoblastic niche supports the growth of quiescent multiple myeloma cells. Blood 123:2204-8
San-Miguel, Jesús; Bladé, Joan; Shpilberg, Ofer et al. (2014) Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 123:4136-42
Srkalovic, Gordan; Hussein, Mohamad A; Hoering, Antje et al. (2014) A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med 3:1275-83
Ocio, Enrique M; Mitsiades, Constantine S; Orlowski, Robert Z et al. (2014) Future agents and treatment directions in multiple myeloma. Expert Rev Hematol 7:127-41

Showing the most recent 10 out of 79 publications